Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab)

Clinical Cancer Research

Volumn 14, Issue 19, 2008, Pages 6154-6160

  Mattes, M Jules ^a   Sharkey, Robert M ^a   Karacay, Habibe ^a   Czuczman, Myron S ^b   Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; EPRATUZUMAB; EPRATUZUMAB Y 90; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VELTUZUMAB; CD20 ANTIGEN; CD22 ANTIGEN; HLL2 AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; YTTRIUM;

ADJUVANT THERAPY; ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; HUMAN; HUMAN CELL; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOACTIVITY; RADIOIMMUNOTHERAPY; ANIMAL; B CELL LYMPHOMA; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CHEMISTRY; DISEASE MODEL; IMMUNOLOGY; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIGENS, CD22; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOGLOBULIN G; LYMPHOMA, B-CELL; MALE; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; YTTRIUM RADIOISOTOPES;

EID: 58149161750     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0404     Document Type: Article

References (37)

1. Chinn P, Braslawsky G, White C, Hanna N. Antibody therapy of non-Hodgkin's B-cell lymphoma. Cancer Immunol Immunother 2003;52:257-80.
2. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22:7359-68.
3. Waldmann TA, Morris JC. Development of antibodies and chimeric molecules for cancer immunotherapy. Adv Immunol 2006;90:83-131.
4. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopex AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004;22:4711-6.
5. Stein R, Qu Z, Chen S, et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 2004;10:2868-78.
6. Leonard JP, Friedberg JW, Younes A, et al. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 2007;18:1216-23.
7. Park SI, Press OW. Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies. Curr Opin Hematol 2007;14:632-8.
8. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219-24.
9. Gopal AK, Press OW, Wilbur SM, Maloney DG, Pagel JM. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45-Ab. Blood 2007;110:161-2a.
10. 90Y-epratuzumab): Do tumor targeting and dosimetry predict therapeutic response? J Nucl Med 2003;44:2000-18.
11. 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res 2005;11:5215-22.
12. 90Y. Clin Cancer Res 2001;7:7:1505-10.
13. Cittera E, Leidi M, Buracchi C, et al. The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradiation of an established lymphoma xenograft by rituximab. J Immunol 2007;178:6616-23.
14. Kennedy AD, Beum PV, Solga MD, et al. Rituxumab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004;172:3280-8.
15. Carnahan J, Stein R, Qu Z, et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 2007;44:1331-41.
16. Michel RB, Mattes MJ. Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells. Clin Cancer Res 2002;8:2701-13.
17. Leung S-O, Goldenberg DM, Dion AS, et al. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. Mol Immunol 1996;32:1413-27.
18. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med 2003;44:77-84.
19. Patel S, Stein R, Ong GL, Goldenberg DM, Mattes MJ. Enhancement of tumor-to-non-tumor localization ratios by hepatocyte-directed blood clearance of antibodies labeled with certain residualizing radiolabels. J Nucl Med 1999;40:1392-401.
20. Sharkey RM, Behr TM, Mattes MJ, et al. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother 1997;44:179-88.
21. Coursey BM, Calhoun JM, Cessna JT. Radioassays of yttrium-90 used in nuclear medicine. Nucl Med Biol 1993;20:693-9.
22. Reddy N, Ong GL, Behr T, Sharkey RM, Goldenberg DM, Mattes MJ. Rapid blood clearance of mouse IgG2a and human IgG1 in nude and nu/+ mice is due to low IgG2a serum concentrations. Cancer Immunol Immunother 1998;46:25-33.
23. Michel RB, Ochakovskaya R, Mattes MJ. Antibody localization to B-cell lymphoma xenografts in immunodeficient mice: importance of using residualizing radiolabels. Clin Cancer Res 2002;8:2632-9.
24. Morschhauser F, Leonard JP, Fayad L, et al. Low doses of humanized anti-CD20 antibody, IMMU-106 (hA20), in refractory or recurrent NHL: phase I/II results. J Clin Oncol 2007;25:8032-3.
25. 90Y-labeled anti-CD22 monoclonal antibody. Clin Cancer Res 2005;11:7920-8.
26. Wei B-R, Ghetie M-A, Vitetta ES. The combined use of an immunotoxin and a radioimmunoconjugate to treat disseminated human B-cell lymphoma in immunodeficient mice. Clin Cancer Res 2000;6:631-42.
27. 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies. Leukemia 2002;16:60-6.
28. Michel RB, Rosario AV, Andrews PM, Goldenberg DM, Mattes MJ. Therapy of small s.c. B-lymphoma xenografts with antibodies conjugated to radionuclides emitting low-energy electrons. Clin Cancer Res 2005;11:777-86.
29. Mattes MJ, Shih LB, Govindan SV, et al. The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody. Int J Cancer 1997;71:429-35.
30. 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res 1992;52:6476-81.
31. Sharkey RM, Natale A, Goldenberg DM, Mattes MJ. Rapid blood clearance of immunoglobulin G2a and immunoglobulin G2b in nude mice. Cancer Res 1991;51:102-7.
32. Hooijberg E, Sein JJ, van den Berk PC, et al. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2. Cancer Res 1995;55:2627-34.
33. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000;6:443-6.
34. Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, et al. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res 2003;9:5866-73.
35. 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts. Blood 2003;101:3641-7.
36. Du Y, Honeychurch J, Cragg MS, et al. Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood 2004;103:1485-94.
37. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.